[go: up one dir, main page]

PE20010215A1 - Derivados de sulfonilamina como antagonistas del receptor de bradiquinina - Google Patents

Derivados de sulfonilamina como antagonistas del receptor de bradiquinina

Info

Publication number
PE20010215A1
PE20010215A1 PE2000000549A PE0005492000A PE20010215A1 PE 20010215 A1 PE20010215 A1 PE 20010215A1 PE 2000000549 A PE2000000549 A PE 2000000549A PE 0005492000 A PE0005492000 A PE 0005492000A PE 20010215 A1 PE20010215 A1 PE 20010215A1
Authority
PE
Peru
Prior art keywords
alkyl
formula
bradiquinin
receptor antagonists
diphenylethylamine
Prior art date
Application number
PE2000000549A
Other languages
English (en)
Inventor
Christopher Thomas Brain
William Cantrell
Andrew James Culshaw
Liladhar Waykole
Terance William Hart
Timothy John Ritchie
Edward Karol Dziadulewicz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20010215A1 publication Critical patent/PE20010215A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

SE REFIERE A DERIVADOS DE SULFONILAMINO DE FORMULA IA, DONDE: R5A ES -XA-R6A, -N(R7A)R8A; XA ES PIPERIDINILENO, PIPERAZINILENO; R6A ES H, ALQUILO C1-C4, ALCOXIALQUILO C1-C4, CARBOXIALQUILO C1-C4, ENTRE OTROS; R7A ES AMINOALQUILO C2-C4, MONO O DI-(ALQUILO C1-C5)AMINOALQUILO C2-C5; R8A ES H, ALQUILO C1-C4, R7A; X1 ES UN GRUPO DIVALENTE DE FORMULA IA`; n ES 0-1; X3 ES CH, N; a) X4 ES UN ENLACE, R3A, R4A SON JUNTOS ETILENO Y m ES 2; b) X4 ES UN ENLACE, R3A ES H, ALQUILO C1-C4, CICLOALQUILO C3-C6, ALQUENILO C3-C6, ENTRE OTROS, R4A ES H, Y m ES 1-3; c) X4 ES CH(R12), R3A ES H Y R4A Y R12 JUNTOS SON PROPILENO, m ES 1 O ETILENO m ES 2; X2 ES UN GRUPO DIVALENTE DE FORMULA IA"; X3 ES CH, N; R11 ES ALQUILO C1-C4, CICLOALQUILO C3-C6, NR1AR2A; R1A Y R2A SON ALQUILO C1-C4 O JUNTO A N FORMAN UN ANILLO HETEROCICLICO C5-C7; R9 Y R10 SON FENILO, PIRIDINA. UN COMPUESTO PREFERIDO ES AMIDA DE 2-(2,2-DIFENILETILAMINO)-5-(4-AMINOCARBONIL-PIPERIDIN-1-SULFONIL)-BENZOICO, AMIDA DE ACIDO 2-(2,2-DIFENILETILAMINO)-5-(AMINOCARBONIL-ALQUILENO DE C2 A C4-AMINOSULFONIL)-BENZOICO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO DE FORMULA IA ES UN ANTAGONISTA DEL RECEPTOR BK1 DE BRADIQUININA Y PUEDE SER UTIL COMO AGENTE ANTIINFLAMATORIO
PE2000000549A 1999-06-04 2000-06-02 Derivados de sulfonilamina como antagonistas del receptor de bradiquinina PE20010215A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9913079.1A GB9913079D0 (en) 1999-06-04 1999-06-04 Organic compounds

Publications (1)

Publication Number Publication Date
PE20010215A1 true PE20010215A1 (es) 2001-03-22

Family

ID=10854785

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000549A PE20010215A1 (es) 1999-06-04 2000-06-02 Derivados de sulfonilamina como antagonistas del receptor de bradiquinina

Country Status (28)

Country Link
US (1) US6958331B1 (es)
EP (1) EP1183233B1 (es)
JP (1) JP3820148B2 (es)
KR (1) KR100479896B1 (es)
CN (1) CN1165522C (es)
AR (1) AR033945A1 (es)
AT (1) ATE305920T1 (es)
AU (1) AU765628B2 (es)
BR (1) BR0011329A (es)
CA (1) CA2372575C (es)
CZ (1) CZ20014302A3 (es)
DE (1) DE60022999T2 (es)
ES (1) ES2250144T3 (es)
GB (1) GB9913079D0 (es)
HK (1) HK1045834A1 (es)
HU (1) HUP0201524A3 (es)
IL (1) IL146112A0 (es)
MX (1) MXPA01012473A (es)
NO (1) NO20015779D0 (es)
NZ (1) NZ515304A (es)
PE (1) PE20010215A1 (es)
PL (1) PL352056A1 (es)
RU (1) RU2001135802A (es)
SK (1) SK17492001A3 (es)
TR (1) TR200103108T2 (es)
TW (1) TWI227224B (es)
WO (1) WO2000075107A2 (es)
ZA (1) ZA200109891B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141609B2 (en) * 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
KR100296463B1 (ko) 1992-08-25 2001-10-24 죤 에이치. 뷰센 레트로바이러스프로테아제저해제로서유용한히드록시에틸아미노술폰아미드
US7109203B2 (en) 2001-05-14 2006-09-19 Novartis Ag Sulfonamide derivatives
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
CA2423876C (en) 2003-04-01 2013-05-28 Universite De Sherbrooke Novel selective bradykinin (bk) b1 peptidic receptor antagonists and uses thereof
CA2522084A1 (en) * 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
WO2008153967A1 (en) * 2007-06-08 2008-12-18 Contec Therapeutics, Inc. Bk1 antagonist conjugates
EP2316820A1 (en) 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
KR20150003771A (ko) 2012-05-03 2015-01-09 노파르티스 아게 그렐린 수용체 효능제로서의 2,7-디아자-스피로[4.5]데스-7-일 유도체의 l-말레이트 염 및 그의 결정질 형태
HRP20220429T1 (hr) 2017-11-24 2022-05-27 Pharvaris Netherlands B.V. Novi antagonisti receptora bradikinina b2
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
UY38707A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
KR102825097B1 (ko) 2022-06-21 2025-06-24 정인호 균일한 고기 익힘 상태를 제공하는 숯불 고기 구이기

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743562B1 (fr) 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
JP2003501413A (ja) 2003-01-14
ZA200109891B (en) 2002-10-01
TWI227224B (en) 2005-02-01
KR100479896B1 (ko) 2005-03-30
ATE305920T1 (de) 2005-10-15
TR200103108T2 (tr) 2002-04-22
MXPA01012473A (es) 2002-06-04
WO2000075107A3 (en) 2001-09-07
ES2250144T3 (es) 2006-04-16
NZ515304A (en) 2004-01-30
CN1165522C (zh) 2004-09-08
DE60022999D1 (de) 2006-02-16
AU765628B2 (en) 2003-09-25
CA2372575C (en) 2010-03-16
AU5528200A (en) 2000-12-28
HUP0201524A2 (en) 2002-08-28
AR033945A1 (es) 2004-01-21
CN1353690A (zh) 2002-06-12
CZ20014302A3 (cs) 2002-03-13
NO20015779L (no) 2001-11-27
GB9913079D0 (en) 1999-08-04
RU2001135802A (ru) 2003-08-27
KR20020005768A (ko) 2002-01-17
BR0011329A (pt) 2002-03-05
DE60022999T2 (de) 2006-06-22
PL352056A1 (en) 2003-07-28
EP1183233A2 (en) 2002-03-06
EP1183233B1 (en) 2005-10-05
HUP0201524A3 (en) 2005-05-30
US6958331B1 (en) 2005-10-25
SK17492001A3 (sk) 2002-04-04
HK1045834A1 (zh) 2002-12-13
CA2372575A1 (en) 2000-12-14
WO2000075107A2 (en) 2000-12-14
NO20015779D0 (no) 2001-11-27
JP3820148B2 (ja) 2006-09-13
IL146112A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
PE20010215A1 (es) Derivados de sulfonilamina como antagonistas del receptor de bradiquinina
LU88769I2 (fr) Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
ES8701173A1 (es) Procedimiento para la fabricacion de derivados de pirazol tienil condensados
CO5070570A1 (es) DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE
ES8802517A1 (es) Un procedimiento para preparar fenoxialquil (substituido con heterocido)-isoxazoles y furanos.
PL182291B1 (pl) Nowe zwiazki, pochodne oksazolidynonu, sposób ich wydarzania i preparat farmaceutyczny PL PL PL PL
ES8602720A1 (es) Un procedimiento para la preparacion de nuevos derivados de 8-cloro-1,5-benzotiazepina
CO5150238A1 (es) Polimorfos de telmisartan, procedimiento para su preparacion y su empleo para la preparacion de un medicamento
DE3061883D1 (en) Imidazole guanidines, their preparation and compositions containing them
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
MY109337A (en) Phenoxyl-and phenoxyalkyl-piperidines as antiviral agents
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
ES551274A0 (es) Un procedimiento para la sintesis de derivados de imidazol.
SE8505715D0 (sv) Indolderivat
DK474089D0 (da) Indolderivater og fremgangsmaader til fremstilling deraf
ZA919954B (en) Phenylalkylaminoalkyl compounds and methods for the preparation thereof and medicaments containing these compounds
EP0810215A4 (en) NOVEL BENZAMIDINE DERIVATIVES AND THEIR MEDICINAL COMPOSITION
CO5180536A1 (es) Inhibidores de proteasas catepsina
DE3461375D1 (en) 1-acetonyl-2-(phenylimino)-imidazolidines, their addition salts, their pharmaceutical compositions and their preparation
GB1109848A (en) New dibenzocycloheptadiene derivatives and process for their preparation
SE8301725L (sv) Substituerade 3,4-diamino-1,2,5-tiadiazoler med histamin-h?712-receptor-antagonistaktivitet
ES536415A0 (es) Procedimiento para preparar la n-(3-trifluorometilfenil)-n'-propargil-piperazina
ES8702881A1 (es) Un procedimiento para la preparacion de etanodiimidamidas
DK443784A (da) Pyrrolylaminopiperidiner, fremgangsmaade til fremstilling deraf samt deres anvendelse som laegemiddel
ES544711A0 (es) Procedimiento para la obtencion de iminosulfonamidas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed